[go: up one dir, main page]

ES2269118T5 - Antagonistas de HMG1 para el tratamiento de afecciones inflamatorias - Google Patents

Antagonistas de HMG1 para el tratamiento de afecciones inflamatorias Download PDF

Info

Publication number
ES2269118T5
ES2269118T5 ES00915762.9T ES00915762T ES2269118T5 ES 2269118 T5 ES2269118 T5 ES 2269118T5 ES 00915762 T ES00915762 T ES 00915762T ES 2269118 T5 ES2269118 T5 ES 2269118T5
Authority
ES
Spain
Prior art keywords
treatment
inflammatory conditions
hmg1 antagonists
hmg1
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES00915762.9T
Other languages
English (en)
Other versions
ES2269118T3 (es
Inventor
Kevin J. Tracey
Haichao Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Feinstein Institutes for Medical Research
Original Assignee
Feinstein Institutes for Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22939703&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2269118(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Feinstein Institutes for Medical Research filed Critical Feinstein Institutes for Medical Research
Application granted granted Critical
Publication of ES2269118T3 publication Critical patent/ES2269118T3/es
Publication of ES2269118T5 publication Critical patent/ES2269118T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/241—Tumor Necrosis Factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6875—Nucleoproteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/067—Pancreatitis or colitis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/125—Adult respiratory distress syndrome
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G01N2800/245—Transplantation related diseases, e.g. graft versus host disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/26—Infectious diseases, e.g. generalised sepsis
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12

Claims (1)

  1. imagen1
    imagen2
ES00915762.9T 1999-02-11 2000-02-11 Antagonistas de HMG1 para el tratamiento de afecciones inflamatorias Expired - Lifetime ES2269118T5 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US248574 1999-02-11
US09/248,574 US6303321B1 (en) 1999-02-11 1999-02-11 Methods for diagnosing sepsis
PCT/US2000/003583 WO2000047104A2 (en) 1999-02-11 2000-02-11 Antagonists of hmg1 for treating inflammatory conditions

Publications (2)

Publication Number Publication Date
ES2269118T3 ES2269118T3 (es) 2007-04-01
ES2269118T5 true ES2269118T5 (es) 2017-05-31

Family

ID=22939703

Family Applications (1)

Application Number Title Priority Date Filing Date
ES00915762.9T Expired - Lifetime ES2269118T5 (es) 1999-02-11 2000-02-11 Antagonistas de HMG1 para el tratamiento de afecciones inflamatorias

Country Status (11)

Country Link
US (12) US6303321B1 (es)
EP (4) EP2362221A1 (es)
JP (3) JP4812166B2 (es)
AT (1) ATE327764T1 (es)
AU (1) AU782984B2 (es)
CA (1) CA2359926C (es)
DE (1) DE60028358T3 (es)
DK (1) DK1165110T3 (es)
ES (1) ES2269118T5 (es)
PT (1) PT1165110E (es)
WO (1) WO2000047104A2 (es)

Families Citing this family (131)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6387639B1 (en) * 1998-11-10 2002-05-14 Sloan-Kettering Institute For Cancer Research Ma family polypeptides and anti-Ma antibodies
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7151082B2 (en) * 1999-02-11 2006-12-19 The Feinstein Institute For Medical Research Antagonists of HMG1 for treating inflammatory conditions
US20060154319A1 (en) * 1999-04-29 2006-07-13 Flodgaard Hans J Inhibition of bradykinin release
US6610713B2 (en) * 2000-05-23 2003-08-26 North Shore - Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US8914114B2 (en) 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
ITMI20010562A1 (it) * 2001-03-16 2002-09-16 Marco E Bianchi Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari
US20030060410A1 (en) * 2001-05-15 2003-03-27 North Shore Long Island Jewish Research Institute Use of HMG fragments as anti-inflammatory agents
US7304034B2 (en) * 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US7220723B2 (en) * 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
US7235358B2 (en) 2001-06-08 2007-06-26 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US6905827B2 (en) 2001-06-08 2005-06-14 Expression Diagnostics, Inc. Methods and compositions for diagnosing or monitoring auto immune and chronic inflammatory diseases
US7026121B1 (en) 2001-06-08 2006-04-11 Expression Diagnostics, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
JP5055598B2 (ja) * 2001-07-13 2012-10-24 株式会社シノテスト ヒトｈｍｇ−１に特異的に結合する抗体を用いるヒトｈｍｇ−１の免疫学的測定方法及び免疫学的測定試薬
ITMI20011986A1 (it) * 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
US7465555B2 (en) * 2002-04-02 2008-12-16 Becton, Dickinson And Company Early detection of sepsis
DE60326453D1 (de) 2002-07-03 2009-04-16 Ct Cardiologico Monzino S P A Die verwendung von hmgb1 zur behandlung von gewebeverletzungen und/oder zur unterstützung der gewebewiederherstellung
CA2491026A1 (en) * 2002-07-05 2004-01-15 The University Of British Columbia Diagnosis of sepsis using mitochondrial nucleic acid assays
GB0226251D0 (en) * 2002-11-11 2002-12-18 San Raffaele Centro Fond Acetylated protein
WO2004044555A2 (en) * 2002-11-12 2004-05-27 Becton, Dickinson And Company Diagnosis of sepsis or sirs using biomarker profiles
WO2004044554A2 (en) * 2002-11-12 2004-05-27 Becton, Dickinson And Company Diagnosis of sepsis or sirs using biomarker profiles
CN1742087A (zh) * 2002-11-12 2006-03-01 贝克顿迪金森公司 使用生物标记谱诊断脓毒或者sirs
CA2506328A1 (en) * 2002-11-20 2004-06-03 Critical Therapeutics, Inc. Use of hmgb fragments as anti-inflammatory agents
US20040141948A1 (en) * 2002-11-20 2004-07-22 Critical Therapeutics, Inc. Use of HMGB fragments as anti-inflammatory agents
EP1567544A4 (en) * 2002-11-20 2009-07-22 Long Island Jewish Res Inst USE OF HMGB POLYPEPTIDES TO IMPROVE THE IMMUNE REACTIONS
US20040156851A1 (en) * 2002-11-20 2004-08-12 Critical Therapeutics, Inc. HMGB1 combination therapies
ATE378048T1 (de) 2002-12-06 2007-11-15 The Feinstein Inst Medical Res Hemmung von entzündungen unter verwendungvon alpha-7-rezeptor verbindenden cholinergen agonisten
WO2004079368A2 (en) 2003-03-08 2004-09-16 Auvation Ltd Markers for colorectal cancer
US7892745B2 (en) 2003-04-24 2011-02-22 Xdx, Inc. Methods and compositions for diagnosing and monitoring transplant rejection
US20090069227A9 (en) * 2003-04-29 2009-03-12 Capogrossi Maurizio C Use of HMGB1 to promote stem cell migration and/or proliferation
FR2855832B1 (fr) * 2003-06-03 2007-09-14 Biomerieux Sa Procede de diagnostic et/ou de pronostic d'un syndrome septique
US7696169B2 (en) * 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
EP1668035A2 (en) 2003-09-11 2006-06-14 Critical Therapeutics, Inc. Monoclonal antibodies against hmgb1
WO2005028512A1 (en) * 2003-09-19 2005-03-31 Leukotech A/S Pro-inflammatory and anti-inflammatory antibodies against the heparin-binding protein (hbp)
US20050148029A1 (en) * 2003-09-29 2005-07-07 Biosite, Inc. Methods and compositions for determining treatment regimens in systemic inflammatory response syndromes
US20050164238A1 (en) * 2003-09-29 2005-07-28 Biosite, Inc. Methods and compositions for the diagnosis of sepsis
US20050196817A1 (en) * 2004-01-20 2005-09-08 Molecular Staging Inc. Biomarkers for sepsis
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
AU2005225458B2 (en) 2004-03-25 2008-12-04 The Feinstein Institutes For Medical Research Neural tourniquet
EP1768698A4 (en) * 2004-06-17 2009-01-28 Medimmune Inc IMMUNOGENIC COMPOSITIONS COMPRISING HMGB1 POLYPEPTIDES
US20080075728A1 (en) * 2004-07-20 2008-03-27 Walter Newman Combination Therapies Of Hmgb And Complement Inhibitors Against Inflammation
WO2006024547A2 (en) * 2004-09-03 2006-03-09 Creabilis Therapeutics S.P.A. Protease resistant human and non-human hmgb1 box-a mutants and their therapeutic/diagnostic use
US7645575B2 (en) 2004-09-08 2010-01-12 Xdx, Inc. Genes useful for diagnosing and monitoring inflammation related disorders
US8129130B2 (en) 2004-10-22 2012-03-06 The Feinstein Institute For Medical Research High affinity antibodies against HMGB1 and methods of use thereof
CN102731654A (zh) * 2004-10-22 2012-10-17 米迪缪尼有限公司 抗hmgb1的高亲和力抗体及其用法
US20080050832A1 (en) * 2004-12-23 2008-02-28 Buechler Kenneth F Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
DE602005025020D1 (de) 2004-12-27 2011-01-05 The Feinstein Inst Medical Res Behandlung von entzündlichen erkrankungen durch el
US20060157647A1 (en) * 2005-01-18 2006-07-20 Becton, Dickinson And Company Multidimensional liquid chromatography/spectrometry
ITRM20050032A1 (it) * 2005-01-21 2006-07-22 Marco E Bianchi Inibitori ed antagonisti di hmgb1 in grado di inibire la patogenesi e la progressione della malattia aterosclerotica.
FR2881437B1 (fr) 2005-01-31 2010-11-19 Biomerieux Sa Procede pour le diagnostic/pronostic d'un syndrome septique
EP1869463A4 (en) 2005-04-15 2010-05-05 Becton Dickinson Co SEPSIS DIAGNOSIS
US20100040607A1 (en) * 2005-05-13 2010-02-18 Tracey Kevin J Combination Therapy with Inhibitors of HMGB and Caspase for the Treatment of Inflammatory Diseases
US8354106B2 (en) 2005-06-16 2013-01-15 The Feinstein Institute For Medical Research Antibodies against HMGB1 and fragments thereof
JP2008546805A (ja) 2005-06-23 2008-12-25 メディミューン，エルエルシー 最適な凝集および断片化プロフィールを有する抗体製剤
US20100040608A1 (en) * 2005-07-18 2010-02-18 Marie Wahren-Herlenius Use of HMGB1 antagonists for the treatment of inflammatory skin conditions
WO2007031100A1 (en) * 2005-09-14 2007-03-22 Ostini, Marco Active immunotherapy of life-threatening systemic inflammation
JP3876325B1 (ja) * 2005-10-24 2007-01-31 国立大学法人 岡山大学 脳梗塞抑制剤
US20100172909A1 (en) * 2005-10-24 2010-07-08 Masahiro Nishibori Cerebral edema suppressant
CA2631212A1 (en) * 2005-11-28 2007-07-05 Medimmune, Llc Antagonists of hmgb1 and/or rage and methods of use thereof
WO2007130725A2 (en) 2006-02-06 2007-11-15 University Of Pittsburgh Of The Commonwealth System Of Higher Education Use of hmgb1 for protection against ischemia reperfusion injury
US8570881B2 (en) * 2006-03-28 2013-10-29 Advanced Micro Devices, Inc. Transmitter voltage and receiver time margining
US7986727B2 (en) * 2006-03-28 2011-07-26 Globalfoundries Inc. In-band method to configure equalization levels
JP3882090B1 (ja) 2006-05-19 2007-02-14 国立大学法人 岡山大学 脳血管攣縮抑制剤
US7993832B2 (en) 2006-08-14 2011-08-09 Xdx, Inc. Methods and compositions for diagnosing and monitoring the status of transplant rejection and immune disorders
PT2065432E (pt) † 2006-09-20 2012-01-10 Asahi Kasei Chemicals Corp Membrana microporosa de poliolefina e separador para baterias de eletrólitos não aquosos
US8148067B2 (en) 2006-11-09 2012-04-03 Xdx, Inc. Methods for diagnosing and monitoring the status of systemic lupus erythematosus
TW200846366A (en) * 2007-02-15 2008-12-01 Univ Fukuoka Agent for suppressing rejection in organ transplantation comprising anti-hmgb-1 antibody
WO2008099913A1 (ja) * 2007-02-15 2008-08-21 Kumamoto University ヒトhmgb-1に特異的に結合する抗体を有効成分として含有する治療剤
EP2123299A4 (en) * 2007-02-15 2011-10-05 Univ Kyushu Nat Univ Corp THERAPEUTIC AGENT FOR INTERSTITIAL PULMONARY DISEASE COMPRISING ANTI-HMGB-1 ANTIBODY
US8221995B2 (en) * 2007-03-23 2012-07-17 Seok-Won Lee Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US20090004755A1 (en) * 2007-03-23 2009-01-01 Biosite, Incorporated Methods and compositions for diagnosis and/or prognosis in systemic inflammatory response syndromes
US20100255513A1 (en) * 2007-03-30 2010-10-07 Denson Lee A Serological markers of inflammatory bowel disease phenotype and disease progression
GB0711327D0 (en) * 2007-06-12 2007-07-25 Hansa Medical Ab Diagnostic method
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
WO2009029614A1 (en) 2007-08-27 2009-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
US20090208513A1 (en) * 2007-09-07 2009-08-20 University Of Pittsburgh - Of The Commonwealth System Of Higher Education Diagnostic And Therapeutic Uses Of Augmenter Of Liver Regeneration In Inflammatory Conditions
JP5224325B2 (ja) * 2007-10-15 2013-07-03 国立大学法人 岡山大学 Ｂ細胞悪性リンパ腫治療薬
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
US9211409B2 (en) 2008-03-31 2015-12-15 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of T-cell activity
US8669113B2 (en) 2008-04-03 2014-03-11 Becton, Dickinson And Company Advanced detection of sepsis
CN102215909B (zh) 2008-11-18 2014-09-10 赛博恩特医疗器械公司 优化用于消炎刺激的电极放置的装置和方法
EP2376923A4 (en) * 2008-12-22 2012-08-15 Children S Res Inst METHOD FOR DETECTING SEPSIS
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
EP2440284B1 (en) 2009-06-09 2018-09-12 Setpoint Medical Corporation Nerve cuff with pocket for leadless stimulator
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
WO2014169145A1 (en) 2013-04-10 2014-10-16 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
US20110123483A1 (en) * 2009-11-23 2011-05-26 Deutsches Krebsforschungszentrum Hmgb1 for cancer treatment
WO2011079309A2 (en) 2009-12-23 2011-06-30 Setpoint Medical Corporation Neural stimulation devices and systems for treatment of chronic inflammation
DK2365332T3 (da) * 2010-03-10 2013-08-26 Pasteur Institut HMGB1- og anti-HMGB1-antistoffer i HIV-inficerede patienter, især med neurologiske lidelser
AU2011235296C1 (en) 2010-03-29 2017-05-04 Nationwide Children's Hospital, Inc. Compositions and methods for the removal of biofilms
WO2011127176A2 (en) * 2010-04-06 2011-10-13 The Children's Research Institute Methods for treating or screening for compounds for the treatment of sepsis
JP5786020B2 (ja) 2010-04-16 2015-09-30 アボットジャパン株式会社 関節リウマチを診断する方法および試薬
IT1406051B1 (it) 2010-08-05 2014-02-06 D M G Italia S R L Uso di hmgb1 come marcatore biologico di infiammazione intestinale umana, metodo non invasivo per la sua rilevazione in campioni fecali e kit relativo.
EP2613797B1 (en) 2010-09-09 2015-11-04 University Of Southern California Compositions and methods for the removal of biofilms
GB201016161D0 (en) 2010-09-24 2010-11-10 Hansa Medical Ab Diagnostic method
GB201102108D0 (en) 2011-02-07 2011-03-23 Hansa Medical Ab Diagnostic method
WO2012154865A2 (en) 2011-05-09 2012-11-15 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US12172017B2 (en) 2011-05-09 2024-12-24 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
US9561274B2 (en) 2011-06-07 2017-02-07 University Of Hawaii Treatment and prevention of cancer with HMGB1 antagonists
WO2012170740A2 (en) 2011-06-07 2012-12-13 University Of Hawaii Biomarker of asbestos exposure and mesothelioma
WO2013052643A1 (en) * 2011-10-05 2013-04-11 The Rockefeller University Dimeric bacteriophage lysins
US20130171659A1 (en) * 2011-12-28 2013-07-04 Abbott Japan Co., Ltd. Methods of prognosis and diagnosis of rheumatoid arthritis
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
US20150335763A1 (en) * 2013-01-09 2015-11-26 The Feinstein Institute For Medical Research Hmgb1-binding beads and uses thereof
JP6247646B2 (ja) 2013-01-28 2017-12-13 株式会社イーベック ヒト化抗ｈｍｇｂ１抗体もしくはその抗原結合性断片
US11274144B2 (en) 2013-06-13 2022-03-15 Research Institute At Nationwide Children's Hospital Compositions and methods for the removal of biofilms
US9745366B2 (en) 2013-09-23 2017-08-29 University Of Southern California Compositions and methods for the prevention of microbial infections
US10233234B2 (en) 2014-01-13 2019-03-19 Trellis Bioscience, Llc Binding moieties for biofilm remediation
US11248040B2 (en) 2013-09-26 2022-02-15 Trellis Bioscience, Llc Binding moieties for biofilm remediation
US9840555B2 (en) 2013-11-04 2017-12-12 Li-Te Chin Method for producing human monoclonal antibodies that binds to at least one part of HMGB1
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
WO2016126807A1 (en) 2015-02-03 2016-08-11 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
AU2016303688B2 (en) 2015-07-31 2023-06-15 Research Institute At Nationwide Children's Hospital Peptides and antibodies for the removal of biofilms
CA3007877A1 (en) 2015-12-11 2017-06-15 Ruprecht-Karls-Universitat Heidelberg Combined preparations of pkm2 modulators and hmgb1
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
WO2017127756A1 (en) 2016-01-20 2017-07-27 Setpoint Medical Corporation Control of vagal stimulation
EP3405255B1 (en) 2016-01-20 2025-12-31 Setpoint Medical Corporation IMPLANTABLE MICROSTIMULATORS AND INDUCTION CHARGING SYSTEMS
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
AU2018236271B2 (en) 2017-03-15 2023-12-21 Research Institute At Nationwide Children's Hospital Composition and methods for disruption of bacterial biofilms without accompanying inflammation
WO2019036470A1 (en) 2017-08-14 2019-02-21 Setpoint Medical Corporation TESTING TEST FOR STIMULATION OF NERVE WAVE
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
CN112823038B (zh) 2018-10-05 2025-10-03 国家儿童医院研究所 用于移除生物膜的hmgb1蛋白衍生物
JP7313659B2 (ja) * 2019-03-12 2023-07-25 株式会社シノテスト 試料中のｈｍｇｂ１の測定方法及び測定試薬
CN113939334A (zh) 2019-04-12 2022-01-14 赛博恩特医疗器械公司 迷走神经刺激来处理神经退行性障碍
WO2020227603A1 (en) 2019-05-09 2020-11-12 The Feinstein Institutes For Medical Research Hmgb1 antagonist
EP4566539A1 (en) 2020-05-21 2025-06-11 The Feinstein Institutes for Medical Research Systems and methods for vagus nerve stimulation
WO2022245878A1 (en) 2021-05-17 2022-11-24 Setpoint Medical Corporation Neurostimulation parameter authentication and expiration system for neurostimulation
CN119936405A (zh) * 2025-01-23 2025-05-06 上海市重大传染病和生物安全研究院 血浆IL-1Ra作为生物标志物在儿童脓毒症诊断和预后中的应用

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4678772A (en) * 1983-02-28 1987-07-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Compositions containing glycyrrhizin
JPS6032714A (ja) * 1983-08-01 1985-02-19 Teijin Ltd 鼻腔粘膜に適用するための安定化された粉末状薬学的組成物
US5585344A (en) 1984-03-19 1996-12-17 The Rockefeller University Liver-derived receptors for advanced glycosylation endproducts and uses thereof
JPS62166897A (ja) * 1986-01-20 1987-07-23 Toyo Soda Mfg Co Ltd 核内非ヒストン蛋白質に対するモノクロ−ナル抗体
JPS63135351A (ja) * 1986-11-28 1988-06-07 Sanwa Kagaku Kenkyusho Co Ltd グリチルレチン酸誘導体、その製法及び該化合物を有効成分とする抗潰瘍剤
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
JP2998287B2 (ja) * 1991-03-13 2000-01-11 千寿製薬株式会社 グリチルレチン酸誘導体
US5656272A (en) 1991-03-18 1997-08-12 New York University Medical Center Methods of treating TNF-α-mediated Crohn's disease using chimeric anti-TNF antibodies
ES2341666T3 (es) 1991-12-02 2010-06-24 Medimmune Limited Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos.
IT1253431B (it) 1991-12-02 1995-08-08 Valetudo S R L Preparati farmaceutici per uso topico destinati al trattamento della psoriasi e della dermatite atopica
IT1254321B (it) * 1992-04-10 1995-09-14 Kemiprogress S R L Composizione farmaceutica per il trattamento e la prevenzione delle infiammazioni cutanee e della mucosa orale.
GB9217316D0 (en) * 1992-08-14 1992-09-30 Ludwig Inst Cancer Res Schwann cell mitogenic factor,its preparation and use
EP0727487A1 (en) † 1995-02-17 1996-08-21 K.U. Leuven Research & Development Multiple-tumor aberrant growth genes
JP3472048B2 (ja) 1995-10-09 2003-12-02 鐘淵化学工業株式会社 自己免疫疾患の診断薬
DE19548122A1 (de) 1995-12-21 1997-06-26 Joern Prof Dr Bullerdiek Nukleinsäuresequenzen von Genen der High Mobility Group Proteine sowie Verwendungen derselben
US6323329B1 (en) * 1995-12-21 2001-11-27 Jorn Bullerdiek Nucleic acid sequences of genes encoding high mobility group proteins
US5864018A (en) 1996-04-16 1999-01-26 Schering Aktiengesellschaft Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor
US6171779B1 (en) 1996-07-12 2001-01-09 University Of Medicine & Dentistry Of New Jersey HMGI proteins in cancer
US6720472B2 (en) 1996-07-12 2004-04-13 University Of Medicine And Dentistry Of New Jersey HMGI proteins in cancer and obesity
AU719555B2 (en) * 1996-07-17 2000-05-11 Kaneka Corporation Diagnostic drugs for autoimmune diseases
US7258857B2 (en) 1996-11-22 2007-08-21 The Trustees Of Columbia University In The City Of New York Rage-related methods for treating inflammation
US20030032090A1 (en) 1997-05-07 2003-02-13 Schering Corporation, A New Jersey Corporation Human receptor proteins; related reagents and methods
EP1988166A1 (en) 1997-05-07 2008-11-05 Schering Corporation Human Toll-like receptor proteins, related reagents and methods
IT1291366B1 (it) * 1997-05-14 1999-01-07 Angelini Ricerche Spa Composizione farmaceutica antivirale comprendente acido glicirrizico ed almeno una proteina dotata di attivita' antivirale
ES2343210T3 (es) 1997-10-17 2010-07-26 Genentech, Inc. Homologos de tipo toll humanos.
US20030027260A1 (en) 1997-10-17 2003-02-06 Genentech, Inc. Human Toll homologues
ES2137125B1 (es) 1997-11-18 2000-08-16 Vinyals S A Lab Dr La utilizacion de la sal de zinc del acido glicirretico en preparados contra el acne y las composiciones que contienen dicha sal.
US6783961B1 (en) 1999-02-26 2004-08-31 Genset S.A. Expressed sequence tags and encoded human proteins
IT1299583B1 (it) 1998-05-19 2000-03-16 Vander Way Limited Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica
EP1121454B1 (en) 1998-10-06 2007-11-14 The Trustees of Columbia University in the City of New York Extracellular novel rage binding protein (en-rage) and uses thereof
US7151082B2 (en) 1999-02-11 2006-12-19 The Feinstein Institute For Medical Research Antagonists of HMG1 for treating inflammatory conditions
US6303321B1 (en) * 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US6177077B1 (en) 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
AU3395900A (en) 1999-03-12 2000-10-04 Human Genome Sciences, Inc. Human lung cancer associated gene sequences and polypeptides
TWI221082B (en) 1999-04-14 2004-09-21 Sumitomo Chemical Co Pesticidal compositions
EP1187932A2 (en) 1999-06-04 2002-03-20 Millennium Pharmaceuticals, Inc. Mammalian toll homologues and uses thereof
US6794132B2 (en) 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
GB9927332D0 (en) 1999-11-18 2000-01-12 Leiv Eiriksson Nyfotek As Novel antibody and uses thereof
US6677321B1 (en) 1999-12-09 2004-01-13 Bruce Levin Methods and compositions for treatment of inflammatory disease
GB0001704D0 (en) 2000-01-25 2000-03-15 Glaxo Group Ltd Protein
US6436703B1 (en) 2000-03-31 2002-08-20 Hyseq, Inc. Nucleic acids and polypeptides
AU2001244711A1 (en) 2000-03-31 2001-10-08 Mochida Pharmaceutical Co., Ltd. Tlr/cd14 binding inhibitor
JP2001322276A (ja) * 2000-05-15 2001-11-20 Fuji Xerox Co Ltd インクジェット記録ヘッド、インクジェット記録装置及びヘッド作製方法
MXPA02011618A (es) 2000-05-25 2003-03-10 Schering Corp Proteinas de receptor de humano, reactivos y metodos relacionados.
US7087632B2 (en) 2001-03-05 2006-08-08 Transtech Pharma, Inc. Benzimidazole derivatives as therapeutic agents
GB0015325D0 (en) 2000-06-22 2000-08-16 Danionics As Electrochemical cells
IL157706A0 (en) 2001-03-02 2004-03-28 Medimmune Inc METHODS OF PREVENTING OR TREATING INFLAMMATORY OR AUTOIMMUNE DISORDERS BY ADMINISTERING INTEGRIN alphav beta3 ANTAGONISTS
CN1494425B (zh) 2001-03-05 2011-12-07 特兰斯泰克制药公司 用作治疗剂的羧酰胺衍生物
WO2002074301A1 (en) 2001-03-15 2002-09-26 University Of Pittsburgh Of The Commonwealth System Of Higher Education Method of using pyruvate and/or its derivatives for the treatment of cytokine-mediated inflammatory conditions
ITMI20010562A1 (it) 2001-03-16 2002-09-16 Marco E Bianchi Inibitori o antagonisti della proteina hmg1 per il trattamento di disordini vascolari
JP2004536585A (ja) 2001-05-09 2004-12-09 エール・ユニバーシティ トル／インターロイキン−１受容体アダプタータンパク質（ｔｉｒａｐ）
MXPA03009995A (es) 2001-05-09 2004-06-30 Univ Michigan Uso de composiciones para tratar rosacea.
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US20030060410A1 (en) 2001-05-15 2003-03-27 North Shore Long Island Jewish Research Institute Use of HMG fragments as anti-inflammatory agents
US7220723B2 (en) 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
JP4823465B2 (ja) 2001-07-13 2011-11-24 株式会社シノテスト ヒトｈｍｇ−１に特異的に結合する抗体並びにこの抗体を用いるヒトｈｍｇ−１の免疫学的測定方法及び免疫学的測定試薬
US20030032674A1 (en) 2001-08-13 2003-02-13 Hwang Daniel H. Use of unsaturated fatty acids to treat severe inflammatory diseases
CA2459310A1 (en) 2001-09-07 2003-03-20 The Trustees Of Boston University Method and composition for treating immune complex associated disorders
JP2003088388A (ja) 2001-09-14 2003-03-25 Herikkusu Kenkyusho:Kk 新規な全長ｃＤＮＡ
EP1293566A1 (en) 2001-09-17 2003-03-19 Societe Des Produits Nestle S.A. A soluble toll-like receptor
WO2003057715A2 (en) 2001-12-28 2003-07-17 The Regents Of The University Of California Novel ligand involved in the transmigration of leukocytes .
WO2003075921A2 (en) 2002-03-05 2003-09-18 Transtech Pharma, Inc. Mono- and bicyclic azole derivatives that inhibit the interaction of ligands with rage
DE60326453D1 (de) 2002-07-03 2009-04-16 Ct Cardiologico Monzino S P A Die verwendung von hmgb1 zur behandlung von gewebeverletzungen und/oder zur unterstützung der gewebewiederherstellung
GB0226251D0 (en) 2002-11-11 2002-12-18 San Raffaele Centro Fond Acetylated protein
EP1567544A4 (en) 2002-11-20 2009-07-22 Long Island Jewish Res Inst USE OF HMGB POLYPEPTIDES TO IMPROVE THE IMMUNE REACTIONS
US20040141948A1 (en) 2002-11-20 2004-07-22 Critical Therapeutics, Inc. Use of HMGB fragments as anti-inflammatory agents
CA2506328A1 (en) 2002-11-20 2004-06-03 Critical Therapeutics, Inc. Use of hmgb fragments as anti-inflammatory agents
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
EP1668035A2 (en) 2003-09-11 2006-06-14 Critical Therapeutics, Inc. Monoclonal antibodies against hmgb1
WO2005034952A2 (en) 2003-10-07 2005-04-21 The Feinstein Institute For Medical Research Isoxazole and isothiazole compounds useful in the treatment of inflammation
EP1768698A4 (en) 2004-06-17 2009-01-28 Medimmune Inc IMMUNOGENIC COMPOSITIONS COMPRISING HMGB1 POLYPEPTIDES
EP1771565B1 (en) 2004-07-20 2012-09-05 The Feinstein Institute for Medical Research Rage protein derivatives
JP2008507505A (ja) 2004-07-20 2008-03-13 プロヴィンシア・イタリアーナ・デッラ・コングレガチォーネ・フィリ・デッリマコラータ・コンセチォーネ−イスティトゥト・デルモパティコ・デッリマコラータ−アイ・アール・シー・シー・エス 創傷治癒のためのｈｍｇｂ１の使用
US7901688B2 (en) 2004-08-03 2011-03-08 Transtech Pharma, Inc. Rage fusion proteins
WO2006024547A2 (en) 2004-09-03 2006-03-09 Creabilis Therapeutics S.P.A. Protease resistant human and non-human hmgb1 box-a mutants and their therapeutic/diagnostic use
US8129130B2 (en) 2004-10-22 2012-03-06 The Feinstein Institute For Medical Research High affinity antibodies against HMGB1 and methods of use thereof
CN102731654A (zh) 2004-10-22 2012-10-17 米迪缪尼有限公司 抗hmgb1的高亲和力抗体及其用法
US20100040608A1 (en) 2005-07-18 2010-02-18 Marie Wahren-Herlenius Use of HMGB1 antagonists for the treatment of inflammatory skin conditions
AU2006312847A1 (en) 2005-11-09 2007-05-18 Pharmexa A/S Therapeutic vaccines targeting HMGB1
CA2631212A1 (en) 2005-11-28 2007-07-05 Medimmune, Llc Antagonists of hmgb1 and/or rage and methods of use thereof
KR101544108B1 (ko) 2006-09-08 2015-08-13 애브비 바하마스 리미티드 인터루킨-13 결합 단백질
WO2008076758A2 (en) * 2006-12-13 2008-06-26 William Marsh Rice University Nerolidol, terpene, and terpene derivative synthesis
US20100249038A1 (en) 2007-06-12 2010-09-30 Board Of Regents, University Of Texas System Antagonists of the receptor for advanced glycation end-products (rage)

Also Published As

Publication number Publication date
EP1757937A3 (en) 2007-04-11
WO2000047104A2 (en) 2000-08-17
WO2000047104A3 (en) 2001-10-25
DK1165110T3 (da) 2006-09-25
US20060210565A1 (en) 2006-09-21
US20130028910A1 (en) 2013-01-31
US20030113323A1 (en) 2003-06-19
CA2359926A1 (en) 2000-08-17
US20020102609A1 (en) 2002-08-01
US8138141B2 (en) 2012-03-20
US6468533B1 (en) 2002-10-22
JP2003520763A (ja) 2003-07-08
JP4812166B2 (ja) 2011-11-09
EP1707214A1 (en) 2006-10-04
DE60028358T2 (de) 2007-03-29
ATE327764T1 (de) 2006-06-15
AU3698300A (en) 2000-08-29
CA2359926C (en) 2013-10-22
US7060504B2 (en) 2006-06-13
US20030017155A1 (en) 2003-01-23
US20150322140A1 (en) 2015-11-12
ES2269118T3 (es) 2007-04-01
US8822169B2 (en) 2014-09-02
JP2014031386A (ja) 2014-02-20
US6448223B1 (en) 2002-09-10
EP1165110A2 (en) 2002-01-02
JP5745299B2 (ja) 2015-07-08
US20060240019A1 (en) 2006-10-26
US8053206B2 (en) 2011-11-08
US7572446B2 (en) 2009-08-11
DE60028358D1 (de) 2006-07-06
WO2000047104A9 (en) 2001-11-29
US7537908B2 (en) 2009-05-26
US20090263916A1 (en) 2009-10-22
EP1757937A2 (en) 2007-02-28
EP1165110A4 (en) 2002-08-07
JP2011168593A (ja) 2011-09-01
US6303321B1 (en) 2001-10-16
EP1165110B1 (en) 2006-05-31
US20170129946A1 (en) 2017-05-11
EP1757937B1 (en) 2013-05-15
US20100172905A1 (en) 2010-07-08
EP2362221A1 (en) 2011-08-31
EP1165110B2 (en) 2016-11-16
US7097838B2 (en) 2006-08-29
AU782984B2 (en) 2005-09-15
PT1165110E (pt) 2006-10-31
DE60028358T3 (de) 2017-03-30

Similar Documents

Publication Publication Date Title
ES2269118T5 (es) Antagonistas de HMG1 para el tratamiento de afecciones inflamatorias
ES2252933T5 (es) Sistemas de ascensor
ES2524006T3 (es) Inhibición del crecimiento celular
ES2181153T5 (es) Compuestos de triazinilaminoestilbeno
EE200100483A (et) Põletikuvastaste vahenditena kasutatavad ühendid
PT1206436E (pt) Retinoides para o tratamento de enfisema
DK1465923T3 (da) Corticotroprinafgivende faktor 2-receptoragonister
ES1044084Y (es) Dispositivo para la limpieza de fondos de piscinas.
DE60032283D1 (de) Festkörperbildaufnahmevorrichtung
PT1020370E (pt) Classificador para o abastecimento de pequenas pecas soltas
ES1042673Y (es) Dispositivo para el desempeñado de espejos en cuartos de baño.
AR028359A1 (es) Composicion para el control de artropodos
ES2404090T5 (es) Procedimiento para la producción de un material higiénico esparcible para animales domésticos
ES2643368T3 (es) Procedimiento para la fabricación de lodo orgánico saneado
NO20016341D0 (no) Inhibitorer for integrinet <alfa>v<beta>6
ES2353865T5 (es) Unidades de dosificación diaria de melatonina
ES2307555T5 (es) Instalación de fermentación por inducción
ES1044076Y (es) Dispositivo para la limpieza de fondos de piscinas.
RU2000118409A (ru) Антимутагенное средство
IT1308479B1 (it) Dispositivo per la formazione di immagini ad effetto zoom
ES1048303Y (es) Estructura perfeccionada para el soporte de aplacados.
ES1043080Y (es) Portalanza para el posicionado automatico de tuercas.
ES1045911Y (es) Estuche para almacenaje de fotografias.
IT248663Y1 (it) Struttura di supporto per l'esposizione di oggetti.
ES1051335Y (es) Dispositivo para el soporte de aplacados